|Bid||270.23 x 900|
|Ask||270.61 x 1000|
|Day's Range||262.45 - 271.30|
|52 Week Range||223.25 - 363.92|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||10.90|
|Earnings Date||Apr 20, 2021 - Apr 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||289.76|
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly executives are confident that data from its monoclonal antibody called donanemab will impress.
Shares of Biogen Inc. were down 0.2% in premarket trading on Thursday after the company said it plans to build a gene therapy manufacturing site at its campus in Research Triangle Park region in North Carolina. Biogen expects to offer 90 new jobs at the new facility, which was a total investment of $200 million for the drug maker. Biogen's stock is down 18.8% over the past year, while the broader S&P 500 is up 27.2%.